University of California, Los Angeles

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).

897 total trials 158 currently recruiting 622 completed early-phase tilt top decile by trial count

University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.

University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.

Top-decile sponsor footprint

University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

897 total, page 17 of 18

COMPLETED Phase 2

A Multicenter Study of NAP (AL-108) in Schizophrenia

NCT00505765

COMPLETED Phase 2

Treatment Study for Cognitive Deficits in Schizophrenia

NCT00505076

COMPLETED NA

Randomized Crossover Study of Magnesium Supplementation

NCT00737815

COMPLETED NA

Effects of Naturally Silicon-Rich Water on Bone Metabolism in Women

NCT01067508

COMPLETED Phase 1

Walking Study for Stroke Rehabilitation

NCT00428480

COMPLETED NA

Study of Tibial Shaft Fractures in Children

NCT01238523

COMPLETED NA

Early Family-Focused Treatment for Youth at Risk for Bipolar Disorder

NCT00943085

COMPLETED Phase 2

Modafinil vs Placebo for the Treatment of Methamphetamine Dependence

NCT00469508

COMPLETED Phase 2

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00451204

COMPLETED

Impulsivity in Pathological Gambling

NCT00580567

COMPLETED

Central Venous Saturation (ScvO2) Monitoring in Pediatric Patients Undergoing Cardiac Surgery

NCT00883922

COMPLETED

A Study Comparing Shunt Placement Versus Endoscopic Third Ventriculostomy in the Treatment of Hydrocephalus

NCT01115270

COMPLETED

Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)

NCT01546766

COMPLETED Early Phase 1

Cytokine-Associated Depression and Social Pain

NCT00949845

COMPLETED NA

Evaluating a Low-Literacy Discharge Medication Education Tool

NCT00408733

COMPLETED Phase 4

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

NCT00429273

COMPLETED Phase 1

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

NCT00408538

COMPLETED

Anorectal Microbicide Project(AMP): Rectal Health, Behaviors and Microbicide Acceptability

NCT00377221

COMPLETED Phase 3

Increasing Hepatitis B Screening Among Korean Church Attendees

NCT00760721

COMPLETED

Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

NCT00670709

COMPLETED NA

Optimizing Outcomes Using Suboxone for Opiate Dependence

NCT00591617

COMPLETED Phase 3

Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents

NCT00332098

COMPLETED Phase 3

Repetitive Magnetic Transcranial Stimulation (rTMS) in the Treatment of Generalized Anxiety Disorder (GAD)

NCT00662584

COMPLETED Phase 1

Locomotor Training in Persons With Multiple Sclerosis

NCT00607126

COMPLETED

Study of Capsule Endoscopy to Determine the Accuracy for Detection of Esophageal Varices

NCT01079416

COMPLETED NA

Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)

NCT00329706

COMPLETED

Characteristics of Episodic Ataxia Syndrome

NCT00266760

COMPLETED NA

A Study of Meditation as a Treatment for Epilepsy

NCT00370929

COMPLETED Phase 4

Starting Treatment With Agonist Replacement Therapies (START)

NCT00315341

COMPLETED NA

Four Models of Telephone Support for Stimulant Recovery

NCT00744068

COMPLETED NA

Behavioral Treatment of Insomnia in Aging

NCT00280020

COMPLETED

Effects of Thymectomy During Cardiothoracic Surgery

NCT00263120

COMPLETED Phase 1

Effectiveness of a Family-Based Intervention for Adolescent Suicide Attempters (The SAFETY Study)

NCT00692302

COMPLETED Phase 2

Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV)

NCT00958763

COMPLETED Phase 4

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

NCT00330551

COMPLETED Phase 4

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177

COMPLETED Phase 2

Prometa Pharmacotherapy for Methamphetamine Dependence

NCT00260481

COMPLETED NA

Integrated Behavioral Therapy for Treating Children With Selective Mutism

NCT00458198

COMPLETED Phase 4

Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia

NCT00423943

COMPLETED NA

Family to Family: Psychoeducation to Improve Children's Outcomes in HIV+ Families

NCT01037946

COMPLETED

Amyloid Plaque and Tangle Imaging in Aging and Dementia

NCT00355498

COMPLETED Phase 4

Statin Therapy in Heart Failure: Potential Mechanisms of Benefit

NCT00233480

COMPLETED Phase 4

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

NCT00200902

COMPLETED NA

Enhancing Recovery After Cardiac Surgery

NCT00522717

COMPLETED NA

Well-Child Care Redesign: A New Model of Care for Children in Low-Income Families

NCT02262962

COMPLETED NA

Gender-Responsive Treatment for Women Offenders - 1

NCT00249613

COMPLETED Phase 2

Mindfulness Meditation Training in HIV

NCT00600561

COMPLETED Phase 3

Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder

NCT00674219

COMPLETED Phase 2

Project SHARE (Senior Health and Alcohol Risk Education)

NCT00107640

TERMINATED Phase 4

Use of Risperidone in ECT for Treatment Resistant Depression

NCT00203723

← Previous Page 17 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 112
Phase 2 82
Phase 3 22
Phase 4 76

What is open in the University of California, Los Angeles pipeline

158 recruiting of 897 indexed (18% open); 622 completed (69%).

Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).

Top condition: Depression (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, Los Angeles: open-pipeline peers nationwide

Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20% Total trials Recruiting share University of California, Los AngelesIndiana UniversityHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterConvaTecEndologixNational Institute on Deafness and Other Communication Disorders (NIDCD)NICHD Pelvic Floor Disorders Network
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 897 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of California, Los Angeles page

897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.

  • 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Los Angeles pipeline card: 897 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.